 |
ความคิดเห็นที่ 10 |
เอดส์
มาลาเรีย
โรคเขตร้อน
หลายคนยังไม่ทราบว่าประเทศไทยเป็นศูนย์กลางการวิจัยโรคมาลาเรียของโลก
SEAQUAMAT and AQUAMAT, two large scale trials:
In an effort to improve antimalarial treatment, MORU conducted the SEAQUAMAT (South East Asian Quinine Artesunate Malaria Trial) multicentre trial, operating in Bangladesh, Burma, India and Indonesia. SEAQUAMAT compared parenteral artesunate against quinine for the treatment of severe P. falciparum malaria. The study worked with 1,461 patients with severe malaria, mainly young adults, and demonstrated a survival benefit of 35% in favour of artesunate, decreasing the case fatality rate from 22.4% to 14.7%. The results of this study have directly led to a change in the WHO recommendations, and artesunate is now the first line treatment of severe malaria in adults including pregnant women.
In contrast with Asia, sub-Saharan Africa has much higher transmission rates of P. falciparum - with the majority of the world’s malaria deaths occurring there. Severe malaria in Africa is mainly a childhood disease and is estimated to be responsible for 20 per cent of deaths in African children under five years old. Childhood malaria has slightly different features to that found in adults, and the remarkable findings of the SEAQUAMAT trial in Asian adults cannot be directly translated to African children. Therefore MORU, in collaboration with African partners, is now undertaking a large study called “AQUAMAT” (Africa Quinine Artesunate Malaria Trial) which compares parenteral artesunate with quinine in paediatric cases of severe malaria in nine study sites over eight countries across sub-Saharan Africa (The Gambia, Ghana, Kenya, Mozambique, Nigeria, Rwanda, Tanzania and Uganda). It is planned to include over 5,300 children in the study and results can be expected in 2010.
http://www.tropmedres.ac/research/malaria/
| จากคุณ |
:
bailie 
|
| เขียนเมื่อ |
:
7 ส.ค. 53 15:11:39
|
|
|
|
|
...ฝุ่น
